194 related articles for article (PubMed ID: 7646545)
1. Effects of two distamycin-ellipticine hybrid molecules on topoisomerase I and II mediated DNA cleavage: relation to cytotoxicity.
Riou JF; Grondard L; Naudin A; Bailly C
Biochem Pharmacol; 1995 Jul; 50(3):424-8. PubMed ID: 7646545
[TBL] [Abstract][Full Text] [Related]
2. Reaction of a biscationic distamycin-ellipticine hybrid ligand with DNA. Mode and sequence specificity of binding.
Bailly C; Michaux C; Colson P; Houssier C; Sun JS; Garestier T; Hélène C; Hénichart JP; Rivalle C; Bisagni E
Biochemistry; 1994 Dec; 33(51):15348-64. PubMed ID: 7803398
[TBL] [Abstract][Full Text] [Related]
3. Binding to DNA, cellular uptake and biological activity of a distamycin-ellipticine hybrid molecule.
Bailly C; Leclere V; Pommery N; Colson P; Houssier C; Rivalle C; Bisagni E; Hénichart JP
Anticancer Drug Des; 1993 Apr; 8(2):145-64. PubMed ID: 8494604
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and evaluation of novel ellipticines as potential anti-cancer agents.
Deane FM; O'Sullivan EC; Maguire AR; Gilbert J; Sakoff JA; McCluskey A; McCarthy FO
Org Biomol Chem; 2013 Feb; 11(8):1334-44. PubMed ID: 23314103
[TBL] [Abstract][Full Text] [Related]
5. Various inhibitors of DNA topoisomerases diminish repair-specific DNA incision in UV-irradiated human fibroblasts.
Thielmann HW; Popanda O; Gersbach H; Gilberg F
Carcinogenesis; 1993 Nov; 14(11):2341-51. PubMed ID: 8242865
[TBL] [Abstract][Full Text] [Related]
6. DNA-binding properties of a distamycin-ellipticine hybrid molecule.
Bailly C; O'Huigin C; Houssin R; Colson P; Houssier C; Rivalle C; Bisagni E; Henichart JP; Waring MJ
Mol Pharmacol; 1992 May; 41(5):845-55. PubMed ID: 1588919
[TBL] [Abstract][Full Text] [Related]
7. [In vitro stimulation by ellipticine derivatives of DNA cleavage induced by DNA topoisomerase II: a structure-activity relationship].
Fossé P; Charra M; Paoletti C; Saucier JM; René B
Bull Cancer; 1994 Mar; 81(3):194-202. PubMed ID: 7894127
[TBL] [Abstract][Full Text] [Related]
8. Mammalian topoisomerase II activity is modulated by the DNA minor groove binder distamycin in simian virus 40 DNA.
Fesen M; Pommier Y
J Biol Chem; 1989 Jul; 264(19):11354-9. PubMed ID: 2544590
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of human DNA topoisomerase IIα by two novel ellipticine derivatives.
Vann KR; Ergün Y; Zencir S; Oncuoglu S; Osheroff N; Topcu Z
Bioorg Med Chem Lett; 2016 Apr; 26(7):1809-12. PubMed ID: 26906637
[TBL] [Abstract][Full Text] [Related]
10. Involvement of DNA topoisomerase II in the selective resistance of a mammalian cell mutant to DNA minor groove ligands: ligand-induced DNA-protein crosslinking and responses to topoisomerase poisons.
Smith PJ; Bell SM; Dee A; Sykes H
Carcinogenesis; 1990 Apr; 11(4):659-65. PubMed ID: 2157558
[TBL] [Abstract][Full Text] [Related]
11. Stimulation of topoisomerase II-mediated DNA cleavage by ellipticine derivatives: structure-activity relationship.
Fossé P; René B; Charra M; Paoletti C; Saucier JM
Mol Pharmacol; 1992 Oct; 42(4):590-5. PubMed ID: 1331751
[TBL] [Abstract][Full Text] [Related]
12. Topoisomerase II-mediated DNA cleavage activity induced by ellipticines on the human tumor cell line N417.
Multon E; Riou JF; LeFevre D; Ahomadegbe JC; Riou G
Biochem Pharmacol; 1989 Jul; 38(13):2077-86. PubMed ID: 2544183
[TBL] [Abstract][Full Text] [Related]
13. DNA-drug recognition and effects on topoisomerase II-mediated cytotoxicity. A three-mode binding model for ellipticine derivatives.
Monnot M; Mauffret O; Simon V; Lescot E; Psaume B; Saucier JM; Charra M; Belehradek J; Fermandjian S
J Biol Chem; 1991 Jan; 266(3):1820-9. PubMed ID: 1846365
[TBL] [Abstract][Full Text] [Related]
14. Involvement of topoisomerases in replication, transcription, and packaging of the linear adenovirus genome.
Wong ML; Hsu MT
J Virol; 1990 Feb; 64(2):691-9. PubMed ID: 2153235
[TBL] [Abstract][Full Text] [Related]
15. Binding of a distamycin-ellipticine hybrid molecule to DNA and chromatin: spectroscopic, biochemical, and molecular modeling investigations.
Bourdouxhe C; Colson P; Houssier C; Sun JS; Montenay-Garestier T; Hélène C; Rivalle C; Bisagni E; Waring MJ; Hénichart JP
Biochemistry; 1992 Dec; 31(49):12385-96. PubMed ID: 1463725
[TBL] [Abstract][Full Text] [Related]
16. Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II.
Tewey KM; Chen GL; Nelson EM; Liu LF
J Biol Chem; 1984 Jul; 259(14):9182-7. PubMed ID: 6086625
[TBL] [Abstract][Full Text] [Related]
17. Azatoxin is a mechanistic hybrid of the topoisomerase II-targeted anticancer drugs etoposide and ellipticine.
Cline SD; Macdonald TL; Osheroff N
Biochemistry; 1997 Oct; 36(42):13095-101. PubMed ID: 9335572
[TBL] [Abstract][Full Text] [Related]
18. The sensitivity to DNA topoisomerase inhibitors in L5178Y lymphoma strains is not related to a primary defect of DNA topoisomerases.
Lanza A; Tornaletti S; Stefanini M; Evans HH; Ricanati M; Astaldi Ricotti GC; Pedrini AM
Carcinogenesis; 1993 Sep; 14(9):1759-63. PubMed ID: 8403196
[TBL] [Abstract][Full Text] [Related]
19. Cellular resistance to the antitumor DNA topoisomerase II inhibitor S16020-2: importance of the N-[2(Dimethylamino)ethyl]carbamoyl side chain.
Le Mée S; Chaminade F; Delaporte C; Markovits J; Saucier JM; Jacquemin-Sablon A
Mol Pharmacol; 2000 Oct; 58(4):709-18. PubMed ID: 10999940
[TBL] [Abstract][Full Text] [Related]
20. Distinct patterns of cell cycle disturbance elicited by compounds interfering with DNA topoisomerase I and II activity.
Poot M; Hiller KH; Heimpel S; Hoehn H
Exp Cell Res; 1995 May; 218(1):326-30. PubMed ID: 7537696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
